Adynxx Inc is primarily active in the healthcare and biotechnology industries.

The main competitors of Adynxx Inc in the market include companies such as CoLucid Pharmaceuticals, Centrexion Therapeutics, and Cara Therapeutics.

Adynxx Inc is a renowned biotechnology company specializing in the development of transformative therapeutics for chronic pain conditions. Founded in [year], Adynxx has dedicated its research efforts towards addressing the unmet medical needs of patients suffering from severe pain. The company's innovative approach revolves around its proprietary platform technology, translating groundbreaking discoveries into potential novel treatments. Adynxx's commitment to advancing pain management has led to numerous strategic partnerships and collaborations within the industry. With a strong focus on scientific excellence and patient well-being, Adynxx Inc is poised to play a pivotal role in revolutionizing chronic pain treatment for the benefit of countless individuals worldwide.

Adynxx Inc, a leading biopharmaceutical company, has achieved several significant milestones in its journey. The company's remarkable achievements include successful completion of Phase 2 clinical trials for its innovative therapeutics, obtaining FDA Fast Track designation for its flagship product, and securing strategic partnerships with renowned pharmaceutical companies. Adynxx Inc also received recognition for its groundbreaking research and development efforts, winning prestigious industry awards. These milestones underscore Adynxx Inc's commitment to revolutionizing the field of pain management and improving the lives of patients worldwide.

Adynxx Inc is primarily present in the United States.

Adynxx Inc represents core values of innovation, dedication, and patient-centricity. The company is committed to revolutionizing pain management by developing transformative therapeutics for patients suffering from chronic pain. Adynxx believes in delivering novel solutions that address the underlying causes of pain, aiming for long-lasting and effective relief. With research-driven approaches and a focus on improving patients' quality of life, Adynxx strives to make a significant impact in the field of pain management.

6 analysts currently rate the Adynxx stock: 0 recommend buying, 3 holding and 3 selling.

Adynxx Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Adynxx share trades at 0,00 EUR (0,00 USD).

Adynxx is a biotechnology company specializing in the development of therapies for pain and neurodegenerative diseases. The company was founded in 2007 and is headquartered in San Francisco, California. Adynxx's business model is based on the development of targeted therapy approaches that address the underlying biological mechanisms of pain and neurodegenerative diseases. The company focuses on the identification of novel target molecules that are specific to certain pain and disease mechanisms. These molecules serve as the basis for the development of drugs that target these mechanisms and enable effective treatment. Adynxx has two main business areas: the discovery and development of drug candidates and the provision of research services to partner companies. In the area of drug development, Adynxx focuses on the exploration of target molecules involved in the development of chronic pain and neurodegenerative diseases. The company uses a combination of computer-aided planning, high-throughput screening methods, and extensive in vitro and in vivo testing to identify promising drug candidates. These drugs are then tested in clinical trials to confirm their efficacy and safety in patients. In addition to drug development, Adynxx also offers a range of research services. These include the identification of target molecules for drug development, the optimization of drug candidates, and the conduct of preclinical tests. Adynxx works closely with partner companies to develop customized research solutions tailored to specific needs and challenges. Adynxx has several promising drug candidates in its pipeline targeting different pain and disease mechanisms. One of these drugs is Brivoligide, a promising medication for the treatment of acute postoperative pain. Brivoligide has been tested in clinical trials and has shown promising results. Adynxx is also developing drugs for chronic pain, such as the drug candidate AYX2. AYX2 aims to inhibit pain receptors in the nervous system and has the potential to be an effective treatment option for a range of chronic pain syndromes. In summary, Adynxx is a biotechnology company specializing in the discovery and development of novel therapies for pain and neurodegenerative diseases. The company focuses on the identification of targeted drug candidates that specifically target the underlying biological mechanisms. Adynxx also offers a wide range of research services to provide individualized solutions to its partners. With promising drug candidates like Brivoligide and AYX2, Adynxx is well positioned to play a significant role in pain therapy and improve the lives of millions of patients worldwide.

Liikevaihtoa ei voida laskea Adynxx:lle tällä hetkellä.

Voittoa ei voida laskea Adynxx:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Adynxx:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Adynxx:lle tällä hetkellä.

Adynxx:n Eulpool-laatuscore on 3/10.

Adynxx:n ISIN on US00784D1037. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Adynxx:n WKN on A2PJNF. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Adynxx:n ticker on ADYX. Tämä pörssinoteeraus käytetään Adynxx-osakkeiden kauppaan pörssissä.

Adynxx maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Adynxx kuuluu sektoriin 'Terveydenhuolto'.

Saadaksesi viimeisen osingon Adynxx:sta päivältä määrässä 6,3 USD, sinulla piti olla osake portfoliossasi ennen irtoamispäivää .

Viimeinen osinko maksettiin .

Adynxx:n osingot jaetaan valuutassa USD.